Clinical trial
A Phase 1 Single Ascending Dose Study of COR388 HCl
NCT03331900 is registered in ClinicalTrials.gov with Cortexyme Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Single Ascending Dose Study of COR388 HCl
- Lead sponsor
- Cortexyme Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 11, 2017
- Completion date
- April 2, 2018
- Enrollment
- 34 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy subjects